Limited***no Accidents***loaded***no Reserve Auction*** on 2040-cars

Auto blog

Almost 70 percent of FCA-PSA Groupe models to ride on two PSA platforms

With the merger between PSA Groupe and Fiat Chrysler having been officially announced this week, we still don't know where everything will settle once the process concludes. We covered the catalog of models herded by the combined company's 12 brands, all of which will remain for now. Profound changes must be afoot somewhere, though, else there'd be no reason for the tie-up. Automotive News has a report on one of the big moves, writing that "more than two-thirds of [PSA-FCA] production would be concentrated on just two platforms." Around 2.6 million cars built by the combined company would sit on PSA's Common Modular Platform, also known as the EMP1, for B-segment city cars, entry-level and mid-range C-segment sedans, and compact crossovers. Three million vehicles would ride on the EMP2 architecture intended for C- and D-segment cars and higher-end crossovers. Those figures account for around 5.6 of the 8.7 million vehicles the combined company expects to sell annually. AN didn't mention the Giorgio platform that's already spread throughout the FCA kingdom to support numerous current and future offerings like the next-gen Jeep Grand Cherokee, but did write that "larger Jeep models will continue to use FCA underpinnings." The body-on-frame chassis' under Ram trucks and the Jeep Wrangler and Gladiator should hold pat. We'll wait for word on the fate of the Compact U.S. Wide platform carrying the Chrysler Voyager and Pacifica and Jeep Cherokee. Dodge products with questionable futures are anyone's guess; we've heard the Dodge Durango, still built on a Mercedes-derived platform it shares with the current Grand Cherokee, could go body-on-frame for the next generation, or die and have the Giorgio-based, three-row Jeep Grand Cherokee take its place. More mystery comes with the long-lived LA and LD platforms in the big sedan and coupe trio Chrysler and Dodge still milk quite successfully. And if there were ever a time for the Dodge Journey – last reported as a Giorgio recipient – to modernize or die, we don't know when that time is. Although FCA platforms have been designed with alternative powertrains in mind, AN says the PSA Groupe architectures "are more modern than FCA's equivalent platforms." After PSA acquired GM's Opel/Vauxhall division, the French company didn't waste time moving the Anglo-German products to in-house platforms, helping to put the formerly money-losing operations into the black in just 18 months.

Is it time for American carmakers to give up on dual-clutch transmissions? [w/poll]

Last week, in the midst of Detroit's first days seeking relief in Chapter 9 of the bankruptcy code, Automotive News contributor Larry P. Vellequette penned an editorial suggesting that American car companies raise the white flag on dual clutch transmissions and give up on trying to persuade Americans to buy cars fitted with them. Why? Because, Vellequette says, like CVT transmissions, they "just don't sound right or feel right to American drivers." (Note: In the article, it's not clear if Vellequette is arguing against wet-clutch and dry-clutch DCTs or just dry-clutch DCTs, which is what Ford and Chrysler use.) The article goes on to state that Ford and Chrysler have experimented with DCTs and that both consumers and the automotive press haven't exactly given them glowing reviews, despite their quicker shifts and increased fuel efficiency potential compared to torque-converter automatic transmissions.
Autoblog staffers who weighed in on the relevance of DCTs in American cars generally disagreed with the blanket nature of Vellequette's statement that they don't sound or feel right, but admit that their lack of refinement compared to traditional automatics can be an issue for consumers. That's particularly true in workaday cars like the Ford Focus and Dodge Dart, both of which have come in for criticism in reviews and owner surveys. From where we sit, the higher-performance orientation of such transmissions doesn't always meld as well with the marching orders of everyday commuters (particularly if drivers haven't been educated as to the transmission's benefits and tradeoffs), and in models not fitted with paddle shifters, it's particularly hard for drivers to use a DCT to its best advantage.
Finally, we also note that DCT tuning is very much an evolving science. For instance, Autoblog editors who objected to dual-clutch tuning in the Dart have more recently found the technology agreeable in the Fiat 500L. Practice makes perfect - or at least more acceptable.

Fiat Chrysler says it did not know about Marchionne's illness

ZURICH/MILAN — Fiat Chrysler said it knew nothing about the medical condition of Sergio Marchionne after a Swiss hospital said on Thursday it had been treating the deceased chief executive for more than a year. "Due to medical privacy, the company had no knowledge of the facts relating to Mr. Marchionne's health," a Fiat Chrysler spokesman said. Questions have been raised about how long Marchionne, who died on Wednesday, was ill and how much the company knew before it made the situation public. Marchionne rescued Fiat and Chrysler from bankruptcy after taking the wheel of the Italian carmaker in 2004 and he multiplied Fiat's value 11 times through 14 years of canny dealmaking. He was due to step down at FCA in April next year. "The company was made aware that Mr. Marchionne had undergone shoulder surgery and released a statement about this," the spokesperson said. "On Friday, July 20, the company was made aware with no detail by Mr. Marchionne's family of the serious deterioration in Mr. Marchionne's condition and that as a result he would be unable to return to work. The company promptly took and announced the appropriate action the following day." Asked whether the scope of the statement included the board and the chairman, the company declined to comment. In emailed comments, Marchionne's family confirmed the companies had not been aware of his health conditions. "At the end of last week FCA was made aware Sergio Marchionne would no longer be able to return to work without mentioning any further details," the family said. The announcement of the death of Marchionne, 66, one of the auto industry's most tenacious and respected CEOs, drew tributes from rivals and tears from his closest colleagues on Wednesday. University Hospital Zurich said earlier on Thursday Marchionne had been treated for a serious illness for more than a year before his death. Marchionne had fallen gravely ill after what the company had described as shoulder surgery at a Zurich hospital. He was replaced as chief executive last weekend after Fiat Chrysler (FCA) said his condition had worsened. "Mr. Sergio Marchionne was a patient at USZ. Due to serious illness, he had been the recipient of recurring treatment for more than a year," the hospital said in a statement. "Although all the options offered by cutting-edge medicine were utilized, Mr.